Author/Authors :
Góralczyk, Alicja Department of Rheumatology and Connective Tissue Diseases - University Hospital No. 2, Bydgoszcz, Poland , Kolossa, Katarzyna Department of Rheumatology and Connective Tissue Diseases - University Hospital No. 2, Bydgoszcz, Poland , Waszczak-Jeka, Marzena Medycyna Kliniczna, Warsaw, Poland , Adamczak, Rafał Department of Obstetrics and Gynaecology - University Hospital No. 2, Bydgoszcz, Poland , Jeka, Sławomir Department of Rheumatology and Connective Tissue Diseases - University Hospital No. 2, Bydgoszcz, Poland
Abstract :
Chronic inflammatory diseases often affect women of childbearing age. Since biologic and targeted synthetic disease-modifying antirheumatic drugs (bDMARDs and tsDMARDs) are more available, their use during conception, pregnancy and lactation has become a matter of concern. Current studies prove the safety of innovative therapy in pregnant women and may contribute to its wider use than before in pregnancy and lactation. It mainly concerns tumour necrosis factor α (TNF-α) inhibitors. We searched PubMed using Medical Subject Headings (MeSH) terms and identified relevant studies and guidelines. We present up-to-date knowledge of bDMARDs and tsDMARDs safety in pregnant and breastfeeding women.
Keywords :
bDMARDs , tsDMARDs , inflammatory disease , pregnancy , lactation
